share_log

Utime | 6-K: Report of foreign private issuer (related to financial reporting)

Utime | 6-K: Report of foreign private issuer (related to financial reporting)

联代科技 | 6-K:外国发行人报告(业绩相关)
美股SEC公告 ·  2024/11/16 05:09

Moomoo AI 已提取核心信息

UTime Limited announced on November 7, 2024, that it has entered into a securities purchase agreement with non-U.S. investors to raise approximately $27.9 million through a private placement. The company will issue up to 180 million units at $0.155 per unit, with each unit consisting of one ordinary share and three warrants exercisable at $0.388 per share.The proceeds will be primarily used to develop the company's new pharmaceutical division, focusing on monkeypox vaccine development. The funds will also support laboratory acquisitions, talent recruitment, equipment purchases, and general corporate purposes.The warrants are immediately exercisable upon issuance and will expire after five years. The closing of the offering is subject to shareholder approval and satisfaction of other closing conditions. The warrants include cashless exercise provisions after six months if no effective registration statement is available for the resale of warrant shares.
UTime Limited announced on November 7, 2024, that it has entered into a securities purchase agreement with non-U.S. investors to raise approximately $27.9 million through a private placement. The company will issue up to 180 million units at $0.155 per unit, with each unit consisting of one ordinary share and three warrants exercisable at $0.388 per share.The proceeds will be primarily used to develop the company's new pharmaceutical division, focusing on monkeypox vaccine development. The funds will also support laboratory acquisitions, talent recruitment, equipment purchases, and general corporate purposes.The warrants are immediately exercisable upon issuance and will expire after five years. The closing of the offering is subject to shareholder approval and satisfaction of other closing conditions. The warrants include cashless exercise provisions after six months if no effective registration statement is available for the resale of warrant shares.
UTime有限公司于2024年11月7日宣布,它已与非美国投资者签署了一项证券购买协议,通过定向增发筹集约2790万美元。该公司将以每单位0.155美元的价格发行最多18000万单位,每单位由一股普通股和三个可按每股0.388美元行使的Warrants组成。所得款项将主要用于开发公司的新药品部门,专注于猴痘疫苗的开发。这些资金还将用于实验室收购、人才招聘、设备购买和一般企业用途。Warrants在发行后立即可行使,有效期为五年。该项发行的成交需经股东批准及其他成交条件的满足。如未能提供有效的登记声明以供Warrants股份的转售,Warrants在六个月后将包括无现金行使条款。
UTime有限公司于2024年11月7日宣布,它已与非美国投资者签署了一项证券购买协议,通过定向增发筹集约2790万美元。该公司将以每单位0.155美元的价格发行最多18000万单位,每单位由一股普通股和三个可按每股0.388美元行使的Warrants组成。所得款项将主要用于开发公司的新药品部门,专注于猴痘疫苗的开发。这些资金还将用于实验室收购、人才招聘、设备购买和一般企业用途。Warrants在发行后立即可行使,有效期为五年。该项发行的成交需经股东批准及其他成交条件的满足。如未能提供有效的登记声明以供Warrants股份的转售,Warrants在六个月后将包括无现金行使条款。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息